Home › Pancreatic Ductal Carcinoma › Tennessee › Nashville
Pancreatic Ductal Carcinoma clinical trials in Nashville, TN
4 studies for Pancreatic Ductal Carcinoma are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 2
- Site 09, Nashville
- Site 19, Nashville
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Sarah Cannon Research Institue, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
Pancreatic Ductal Carcinoma trials in other cities
- Boston, MA4 studies
- Scottsdale, AZ3 studies
- Arlington, VA3 studies
- Tampa, FL3 studies
- Orange, CA3 studies
- New York City, NY3 studies
- Houston, TX3 studies
- San Antonio, TX3 studies
- Cincinnati, OH3 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.